Pulmonx: Minimally Invasive Medical Device for Severe Emphysema

8/09/2021 11:45:00 PM

Airway insertion valve to safely treat patients with severe emphysema without surgery – Attracted investment of $66 million

Pulmonx provides minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders ((Less Invasive Treatment Option for Severe Emphysema/COPD).

Pulmonx-Minimally Invasive Medical Device for Severe Emphysema

A non-surgical medical device that relieves dyspnea by installing a valve in the patient's bronchioles for the treatment of the lungs of patients with emphysema who have lost elasticity.

FDA-approved device that uses Zephyr® valves in 25 countries and is installed in bronchioles to reduce lung hyperinflation and gas entrapment in patients with severe emphysema.

Pulmonx

Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.

The company is currently engaged in the design, development and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema.

Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves.

General Information

Headquarters : San Francisco, CA
Founders : Rodney Perkins
Categories : Health Care, Medical Device
Founded : 1998
Contact : info@pulmonx.com

Funding

Investors: Adage Capital Management, Ally Bridge Group, HealthQuest Capital, Partner Fund Management, Rock Springs Capital
Funding Rounds (11) - $276.9M
May 5, 2020 Series H / $66M
May 5, 2020 Debt Financing / $17M
May 9, 2019 Series G / $65M
Jan 1, 2017 Series F / $30M
Sep 17, 2014 Debt Financing / $20M
Jan 31, 2012 Private Equity Round / $10M
Mar 8, 2010 Series C / $32M
Mar 31, 2009 Venture Round / $2.9M
Jul 15, 2008 Debt Financing / $7M
May 7, 2007 Series B / $20M
Dec 10, 2003 Series A / $7.1M